241 related articles for article (PubMed ID: 22858510)
1. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
[TBL] [Abstract][Full Text] [Related]
2. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
[TBL] [Abstract][Full Text] [Related]
4. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
6. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
8. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
[TBL] [Abstract][Full Text] [Related]
9. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
10. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
13. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.
Willis F; Woll P; Theti D; Jamali H; Bacon P; Baker N; Pettengell R
Bone Marrow Transplant; 2009 Jun; 43(12):927-34. PubMed ID: 19169289
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
16. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
Hosing C; Qazilbash MH; Kebriaei P; Giralt S; Davis MS; Popat U; Anderlini P; Shpall EJ; McMannis J; Körbling M; Champlin RE
Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells.
Klein J; Rey P; Dansey R; Karanes C; Abella E; Cassells L; Hamm C; Flowers M; Couwlier C; Peters W; Baynes R
Bone Marrow Transplant; 1999 Nov; 24(9):959-63. PubMed ID: 10556954
[TBL] [Abstract][Full Text] [Related]
20. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.
To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B
Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]